Why, in both ADA and AACE guidelines statements, do GLP-1 receptor agonists represent a foundational approach for management of T2D?

Why, in both ADA and AACE guidelines statements, do GLP-1 receptor agonists represent a foundational approach for management of T2D?

Why, in both ADA and AACE guidelines statements, do GLP-1 receptor agonists represent a foundational approach for management of T2D?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

James Gavin III, MD, PhD

James Gavin III, MD, PhD

Clinical Professor of Medicine
Emory University School of Medicine
Atlanta, Georgia
Clinical Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana